Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 5/20 | 0.47 |
| ▸ | PRF1 | P14222 | 8/20 | 0.45 |
| ▸ | USP1 | O94782 | 3/20 | 0.42 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23502017 | 0.76 | PRKCI (0.50) | PRF1GRM5 | |
| SCHEMBL26174551 | 0.76 | PRKCQ (0.51) | PRF1 | |
| SCHEMBL23501971 | 0.72 | GRIA1 (0.60) | — | |
| SCHEMBL12545696 | 0.71 | NPSR1 (0.41) | UGCGPRF1USP1GRM5 | |
| SCHEMBL15571058 | 0.71 | PRF1 (0.44) | PRF1 | |
| SCHEMBL15571631 | 0.70 | PRF1 (0.47) | PRF1 | |
| SCHEMBL21013541 | 0.70 | PRF1 (0.44) | UGCGPRF1 | |
| SCHEMBL21903245 | 0.70 | MAP3K5 (0.47) | PRF1GRM5GRM1 | |
| SCHEMBL15571453 | 0.69 | PRF1 (0.46) | PRF1 | |
| SCHEMBL19028087 | 0.69 | METAP2 (0.41) | UGCGPRF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | UGCG 161/4885PRF1 307/4885USP1 4652/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | UGCG 161/4885PRF1 307/4885USP1 4652/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | UGCG 161/4885PRF1 307/4885USP1 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.